{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:57:06Z","timestamp":1790776626511,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.humpath.2024.105705","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T07:29:12Z","timestamp":1733815752000},"page":"105705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Primary mediastinal large B-cell lymphoma from the clinic to genomics: Insights for pathologists"],"prefix":"10.1016","volume":"156","author":[{"given":"Najla","family":"Fakhruddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Abou Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6226-419X","authenticated-orcid":false,"given":"Zaher","family":"Chakhachiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2024.105705_bib1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1080\/1042819042000219467","article-title":"Mutational analysis of IgV H and BCL-6 genes suggests thymic B-cells origin of mediastinal (thymic) B-cell lymphoma","volume":"45","author":"Csernus B","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2024.105705_bib2","volume":"vol. 2","author":"Swerdlow Sh","year":"2017"},{"key":"10.1016\/j.humpath.2024.105705_bib3","first-page":"126","article-title":"Primary mediastinal B-cell lymphoma (PMBL): results from the UK NCRI R-CHOP 14 v 21 Trial<Gleeson 2015.pdf>","author":"Gleeson M","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.humpath.2024.105705_bib4","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00277-023-05225-2","article-title":"Primary mediastinal\/thymic diffuse large B-cell lymphoma: a population-based study on incidence and survival","volume":"102","author":"Zhou","year":"2023","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.humpath.2024.105705_bib5","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.105705_bib6","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","article-title":"Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach","volume":"136","author":"Hayden Ar","year":"2020","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.humpath.2024.105705_bib7","doi-asserted-by":"crossref","first-page":"e4054","DOI":"10.1097\/MD.0000000000004054","article-title":"Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis","volume":"95","author":"Liu","year":"2016","journal-title":"Medicine (Baltim)"},{"issue":"7","key":"10.1016\/j.humpath.2024.105705_bib8","first-page":"11","article-title":"Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (\"Groupe d'Etude des Lymphomes de l'Adulte\") study","volume":"20","author":"Cazals-Hatem","year":"1966","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2024.105705_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00428-023-03550-5","article-title":"Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology","volume":"483","author":"Gibson","year":"2023","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.humpath.2024.105705_bib10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/00004728-200411000-00009","article-title":"Primary mediastinal lymphoma: characteristic features of the various histological subtypes on CT","volume":"28","author":"Tateishi","year":"2004","journal-title":"J Comput Assist Tomogr"},{"issue":"10","key":"10.1016\/j.humpath.2024.105705_bib11","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood.V94.10.3567.422k06_3567_3575","article-title":"The MAL gene is expressed in primary mediastinal large B-cell lymphoma","volume":"94","author":"Copie-Bergman","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.humpath.2024.105705_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood-2003-10-3545","article-title":"Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma","volume":"104","author":"Guiter","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.humpath.2024.105705_bib13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.humpath.2024.105705_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1098-2264(2001)9999:9999<::AID-GCC1105>3.0.CO;2-I","article-title":"Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line","volume":"30","author":"Bentz","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.humpath.2024.105705_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.2019001126","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","author":"Mottok","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.humpath.2024.105705_bib16","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/sj.leu.2404919","article-title":"Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH)","volume":"21","author":"Wessendorf","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.humpath.2024.105705_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3324\/haematol.2010.033167","article-title":"Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma","volume":"96","author":"Eberle","year":"2011","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.humpath.2024.105705_bib18","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.humpath.2024.105705_bib19","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.2019002067","article-title":"Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade","volume":"134","author":"Chapuy","year":"2019","journal-title":"Blood"},{"issue":"7338","key":"10.1016\/j.humpath.2024.105705_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.humpath.2024.105705_bib21","first-page":"11","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","author":"Mottok A","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.humpath.2024.105705_bib22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"issue":"23","key":"10.1016\/j.humpath.2024.105705_bib23","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1182\/bloodadvances.2023011169","article-title":"High PDL1\/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma","volume":"7","author":"Camus","year":"2023","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.humpath.2024.105705_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194866","article-title":"Molecular characterization of primary mediastinal large B-cell lymphomas","volume":"15","author":"Donzel","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.humpath.2024.105705_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.23.01053","article-title":"Genetic characterization of primary mediastinal B-cell lymphoma: pathogenesis and patient outcomes","volume":"42","author":"Noerenberg","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.humpath.2024.105705_bib26","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ding","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.humpath.2024.105705_bib27","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2009-03-209759","article-title":"Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma","volume":"114","author":"Ritz","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.humpath.2024.105705_bib28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2008.207","article-title":"Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas","volume":"22","author":"Meier","year":"2009","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2024.105705_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.2900","article-title":"Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma","volume":"46","author":"Gunawardana","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.humpath.2024.105705_bib30","first-page":"7","article-title":"Fig, Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma","volume":"19","author":"Jardin F","year":"2016","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.humpath.2024.105705_bib31","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2017-09-808907","article-title":"Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation","volume":"131","author":"Vigano","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.humpath.2024.105705_bib32","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2005-04-1399","article-title":"Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction","volume":"106","author":"Bea","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.humpath.2024.105705_bib33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/gcc.20420","article-title":"Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein","volume":"46","author":"Weniger","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.humpath.2024.105705_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J Exp Med"},{"issue":"23","key":"10.1016\/j.humpath.2024.105705_bib35","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood-2016-03-704528","article-title":"Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma","volume":"128","author":"Mansouri","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.humpath.2024.105705_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0046-8177(99)90273-3","article-title":"Mediastinal B-cell lymphoma: a study of its histomorphologic spectrum based on 109 cases","volume":"30","author":"Paulli M","year":"1999","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2024.105705_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ajcp\/83.6.676","article-title":"Primary mediastinal non-Hodgkin's lymphomas: a morphologic and immunologic study of 19 cases","volume":"83","author":"Yousem","year":"1985","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2024.105705_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0002-9440(10)63815-1","article-title":"Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins","volume":"162","author":"Pileri Sa","year":"2003","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2024.105705_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1470-2045(02)00714-3","article-title":"Mediastinal (thymic) large B-cell lymphoma: where do we stand?","volume":"3","author":"Barth","year":"2002","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.humpath.2024.105705_bib40","first-page":"9","article-title":"Molecular characterization of primary mediastinal B cell lymphoma","volume":"148","author":"Tsang","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2024.105705_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.anndiagpath.2019.04.009","article-title":"The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma","volume":"40","author":"Aladily","year":"2019","journal-title":"Ann Diagn Pathol"},{"issue":"12","key":"10.1016\/j.humpath.2024.105705_bib42","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/modpathol.2012.129","article-title":"Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers","volume":"25","author":"Dorfman","year":"2012","journal-title":"Mod Pathol"},{"issue":"Sep1","key":"10.1016\/j.humpath.2024.105705_bib43","first-page":"16","article-title":"Primary mediastinal large B-cell lymphoma","volume":"140","author":"Savage","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.humpath.2024.105705_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13000-019-0918-x","article-title":"Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma","volume":"14","author":"Kim","year":"2019","journal-title":"Diagn Pathol"},{"issue":"12","key":"10.1016\/j.humpath.2024.105705_bib45","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.humpath.2024.105705_bib46","doi-asserted-by":"crossref","first-page":"E436","DOI":"10.1002\/ajh.24485","article-title":"The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome","volume":"91","author":"Bledsoe","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2024.105705_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2024.105705_bib48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/PAS.0000000000000771","article-title":"Performance of a commercially available MAL antibody in the diagnosis of primary mediastinal large B-cell lymphoma","volume":"41","author":"Gentry","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2024.105705_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.humpath.2021.05.008","article-title":"Syncytial variant of nodular sclerosis Hodgkin lymphoma: an under-emphasized variant","volume":"117","author":"Wang","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2024.105705_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.humpath.2021.11.007","article-title":"Clinicopathological features of syncytial variant nodular sclerosis Hodgkin lymphoma","volume":"119","author":"Zhang","year":"2022","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2024.105705_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.pap.0000138144.11635.f8","article-title":"Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma","volume":"11","author":"Calvo Kr","year":"2004","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2024.105705_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.path.2023.02.002","article-title":"Hodgkin lymphoma and its differential diagnosis: new twists on an old challenge","volume":"16","author":"Sohani","year":"2023","journal-title":"Surg Pathol Clin"},{"issue":"11","key":"10.1016\/j.humpath.2024.105705_bib53","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.humpath.2024.105705_bib54","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3109\/10428194.2013.810738","article-title":"Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease","volume":"55","author":"Soumerai","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.humpath.2024.105705_bib55","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.clml.2023.08.014","article-title":"Updates in the management of primary mediastinal B cell lymphoma","volume":"23","author":"Soueidy","year":"2023","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"19","key":"10.1016\/j.humpath.2024.105705_bib56","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/bloodadvances.2021004778","article-title":"Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study","volume":"5","author":"Camus","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.humpath.2024.105705_bib57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2016.152256","article-title":"Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association","volume":"102","author":"Sarkozy","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.humpath.2024.105705_bib58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijrobp.2015.02.006","article-title":"Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"10.1016\/j.humpath.2024.105705_bib59","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.humpath.2024.105705_bib60","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41409-017-0063-7","article-title":"Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation","volume":"53","author":"Avivi","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.humpath.2024.105705_bib61","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190802108870","article-title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma","volume":"49","author":"Kuruvilla","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.humpath.2024.105705_bib62","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.humpath.2024.105705_bib63","first-page":"141","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170","volume":"142","author":"Zinzani","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.humpath.2024.105705_bib64","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.humpath.2024.105705_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.humpath.2024.105705_bib66","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.humpath.2024.105705_bib67","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.humpath.2024.105705_bib68","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.3109\/10428194.2014.985673","article-title":"Structural genomic alterations in primary mediastinal large B-cell lymphoma","volume":"56","author":"Twa","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.humpath.2024.105705_bib69","doi-asserted-by":"crossref","first-page":"323","DOI":"10.6004\/jnccn.2023.7004","article-title":"Primary mediastinal B-cell lymphoma in children and young adults","volume":"21","author":"Forlenza","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"12","key":"10.1016\/j.humpath.2024.105705_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3324\/haematol.2021.278971","article-title":"Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma","volume":"106","author":"Kn\u00f6rr F","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.humpath.2024.105705_bib71","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3324\/haematol.2021.280257","article-title":"Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study","volume":"107","author":"Dourthe","year":"2022","journal-title":"Haematologica"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724002144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724002144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T21:41:54Z","timestamp":1741297314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817724002144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":71,"alternative-id":["S0046817724002144"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105705","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary mediastinal large B-cell lymphoma from the clinic to genomics: Insights for pathologists","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105705"}}